You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Linking Inaugural Skin Manifestations With BPDCN: Clinical Pearls for Identification and Management 

  • Authors: Daniel H. Wiseman, MB, ChB, PhD; Naveen Pemmaraju, MD
  • CPD Released: 6/28/2022
  • Valid for credit through: 6/28/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of hematologists, dermatologists, and pathologists outside the United States.

The goal of this activity is for the learners to be better able to improve physician knowledge and confidence in diagnosing and managing patients with BPDCN, an aggressive hematological malignancy associated with inaugural skin manifestations.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Cutaneous manifestation of BPDCN
    • Prevalence of CD123 overexpression in BPDCN
    • Available clinical evidence for managing BPDCN 
  • Have greater confidence related to
    • Identifying patients with BPDCN associated with inaugural skin manifestations 


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Daniel H. Wiseman, MB, ChB, PhD

    Consultant Hematologist
    The Christie NHS Foundation Trust
    Manchester, United Kingdom

    Disclosures

    Daniel H. Wiseman, MB, ChB, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Novartis; StemLine
    Speaker or member of speakers bureau for: Janssen; Novartis

  • Naveen Pemmaraju, MD

    Associate Professor
    Director
    Blastic Plasmacytoid Dendritic Cell Neoplasm Program
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosures

    Naveen Pemmaraju, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Aptitude; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Cimeio Therapeutics; ClearView; CTI Biopharma; Incyte Corporation; Intellisphere; Novartis; Novartis AH; Patient Power; PharmaEssentia; Protagonist; StemLine Therapeutics
    Speaker or member of speakers bureau for: AbbVie, Inc.; Curio; Dava Pharmaceuticals; StemLine Therapeutics
    Research funding from: AbbVie, Inc.; Ascentage Pharma; Celliestis; Daiichi Sankyo, Inc.; MustangBio; Novartis; Plexxikon Inc.; Rafael; SagerStrong; Samus Therapeutics; StemLine Therapeutics

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Linking Inaugural Skin Manifestations With BPDCN: Clinical Pearls for Identification and Management 

Authors: Daniel H. Wiseman, MB, ChB, PhD; Naveen Pemmaraju, MDFaculty and Disclosures

CPD Released: 6/28/2022

Valid for credit through: 6/28/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Focus on Identifying Patients With BPDCN

Dr Wiseman discusses the various clinical manifestations of BPDCN.
Daniel H. Wiseman, MB, ChB, PhD

Focus on Managing Patients With BPDCN

Dr Pemmaraju presents clinical evidence supporting new therapeutic strategies for BPDCN.
Naveen Pemmaraju, MD

Practical Application: Advice From the Clinic

Dr Wiseman and Dr Pemmaraju share experiences in diagnosing and managing patients with BPDCN.
Daniel H. Wiseman, MB, ChB, PhD; Naveen Pemmaraju, MD
 

Educational Impact Challenge

The goal of this activity is for the learners to be better able to improve physician knowledge and confidence in diagnosing and managing patients with BPDCN, an aggressive hematological malignancy associated with inaugural skin manifestations.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print